was read the article
array:24 [ "pii" => "S1578219019303452" "issn" => "15782190" "doi" => "10.1016/j.adengl.2019.11.004" "estado" => "S300" "fechaPublicacion" => "2020-01-01" "aid" => "2259" "copyrightAnyo" => "2019" "documento" => "article" "crossmark" => 1 "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/" "subdocumento" => "crp" "cita" => "Actas Dermosifiliogr. 2020;111:59-62" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 9 "formatos" => array:2 [ "HTML" => 7 "PDF" => 2 ] ] "Traduccion" => array:1 [ "es" => array:19 [ "pii" => "S0001731019303096" "issn" => "00017310" "doi" => "10.1016/j.ad.2019.03.015" "estado" => "S300" "fechaPublicacion" => "2020-01-01" "aid" => "2259" "documento" => "simple-article" "crossmark" => 1 "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/" "subdocumento" => "crp" "cita" => "Actas Dermosifiliogr. 2020;111:59-62" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 41 "formatos" => array:2 [ "HTML" => 25 "PDF" => 16 ] ] "es" => array:14 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">COMUNICACIÓN BREVE</span>" "titulo" => "Atenolol oral en el manejo del hemangioma infantil: serie de casos de 46 pacientes" "tienePdf" => "es" "tieneTextoCompleto" => "es" "tieneResumen" => array:3 [ 0 => "es" 1 => "es" 2 => "en" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "59" "paginaFinal" => "62" ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "Oral Atenolol for Infantile Hemangioma: Case Series of 46 Infants" ] ] "contieneResumen" => array:2 [ "es" => true "en" => true ] "contieneTextoCompleto" => array:1 [ "es" => true ] "contienePdf" => array:1 [ "es" => true ] "resumenGrafico" => array:2 [ "original" => 1 "multimedia" => array:5 [ "identificador" => "fig0015" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => false "mostrarDisplay" => true "figura" => array:1 [ 0 => array:4 [ "imagen" => "fx1.jpeg" "Alto" => 574 "Ancho" => 1333 "Tamanyo" => 63361 ] ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "X. Calderón-Castrat, F. Velásquez, R. Castro, R. Ballona" "autores" => array:4 [ 0 => array:2 [ "nombre" => "X." "apellidos" => "Calderón-Castrat" ] 1 => array:2 [ "nombre" => "F." "apellidos" => "Velásquez" ] 2 => array:2 [ "nombre" => "R." "apellidos" => "Castro" ] 3 => array:2 [ "nombre" => "R." "apellidos" => "Ballona" ] ] ] ] "resumen" => array:1 [ 0 => array:3 [ "titulo" => "Graphical abstract" "clase" => "graphical" "resumen" => "<span id="abst0005" class="elsevierStyleSection elsevierViewall"><p id="spar0005" class="elsevierStyleSimplePara elsevierViewall"><elsevierMultimedia ident="fig0015"></elsevierMultimedia></p></span>" ] ] ] "idiomaDefecto" => "es" "Traduccion" => array:1 [ "en" => array:9 [ "pii" => "S1578219019303452" "doi" => "10.1016/j.adengl.2019.11.004" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1578219019303452?idApp=UINPBA000044" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731019303096?idApp=UINPBA000044" "url" => "/00017310/0000011100000001/v3_202009190630/S0001731019303096/v3_202009190630/es/main.assets" ] ] "itemSiguiente" => array:20 [ "pii" => "S1578219019302471" "issn" => "15782190" "doi" => "10.1016/j.adengl.2019.07.017" "estado" => "S300" "fechaPublicacion" => "2020-01-01" "aid" => "2179" "copyright" => "Elsevier España, S.L.U. and AEDV" "documento" => "simple-article" "crossmark" => 1 "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/" "subdocumento" => "crp" "cita" => "Actas Dermosifiliogr. 2020;111:63-4" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 3 "formatos" => array:2 [ "HTML" => 1 "PDF" => 2 ] ] "en" => array:11 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Case for Diagnosis</span>" "titulo" => "Recurrent Buttock Cellulitis in a Young Man" "tienePdf" => "en" "tieneTextoCompleto" => "en" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "63" "paginaFinal" => "64" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Celulitis glútea de repetición en un varón joven" ] ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0015" "etiqueta" => "Figure 3" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr3.jpeg" "Alto" => 645 "Ancho" => 900 "Tamanyo" => 135755 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">Hematoxylin–eosin, ×200.</p>" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "D. Morgado-Carrasco, P. Giavedoni, J.M. Mascaró" "autores" => array:3 [ 0 => array:2 [ "nombre" => "D." "apellidos" => "Morgado-Carrasco" ] 1 => array:2 [ "nombre" => "P." "apellidos" => "Giavedoni" ] 2 => array:2 [ "nombre" => "J.M." "apellidos" => "Mascaró" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "es" => array:9 [ "pii" => "S0001731019301139" "doi" => "10.1016/j.ad.2018.06.018" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731019301139?idApp=UINPBA000044" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1578219019302471?idApp=UINPBA000044" "url" => "/15782190/0000011100000001/v2_202004200619/S1578219019302471/v2_202004200619/en/main.assets" ] "itemAnterior" => array:20 [ "pii" => "S1578219019303749" "issn" => "15782190" "doi" => "10.1016/j.adengl.2019.12.008" "estado" => "S300" "fechaPublicacion" => "2020-01-01" "aid" => "2248" "copyright" => "AEDV" "documento" => "article" "crossmark" => 1 "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/" "subdocumento" => "fla" "cita" => "Actas Dermosifiliogr. 2020;111:53-8" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "en" => array:13 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Original Article</span>" "titulo" => "Genital Infection With Herpes Simplex Virus Type 1 and Type 2 in Valencia, Spain: A Retrospective Observational Study" "tienePdf" => "en" "tieneTextoCompleto" => "en" "tieneResumen" => array:2 [ 0 => "en" 1 => "es" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "53" "paginaFinal" => "58" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Infecciones genitales por virus herpes tipo 1 y virus herpes tipo 2 en Valencia, España: estudio observacional retrospectivo" ] ] "contieneResumen" => array:2 [ "en" => true "es" => true ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:8 [ "identificador" => "fig0005" "etiqueta" => "Fig. 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 531 "Ancho" => 850 "Tamanyo" => 90275 ] ] "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at0005" "detalle" => "Fig. " "rol" => "short" ] ] "descripcion" => array:1 [ "en" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">Predominantly ulcerative lesions.</p>" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "J. Magdaleno-Tapial, P. Hernández-Bel, C. Valenzuela-Oñate, J.M. Ortiz-Salvador, M García-Legaz-Martínez, Á. Martínez-Domenech, G. Pérez-Pastor, A. Esteve-Martínez, V. Zaragoza-Ninet, J.L. Sánchez-Carazo, V. Alegre-de Miquel, A. Pérez-Ferriols" "autores" => array:12 [ 0 => array:2 [ "nombre" => "J." "apellidos" => "Magdaleno-Tapial" ] 1 => array:2 [ "nombre" => "P." "apellidos" => "Hernández-Bel" ] 2 => array:2 [ "nombre" => "C." "apellidos" => "Valenzuela-Oñate" ] 3 => array:2 [ "nombre" => "J.M." "apellidos" => "Ortiz-Salvador" ] 4 => array:2 [ "nombre" => "M" "apellidos" => "García-Legaz-Martínez" ] 5 => array:2 [ "nombre" => "Á." "apellidos" => "Martínez-Domenech" ] 6 => array:2 [ "nombre" => "G." "apellidos" => "Pérez-Pastor" ] 7 => array:2 [ "nombre" => "A." "apellidos" => "Esteve-Martínez" ] 8 => array:2 [ "nombre" => "V." "apellidos" => "Zaragoza-Ninet" ] 9 => array:2 [ "nombre" => "J.L." "apellidos" => "Sánchez-Carazo" ] 10 => array:2 [ "nombre" => "V." "apellidos" => "Alegre-de Miquel" ] 11 => array:2 [ "nombre" => "A." "apellidos" => "Pérez-Ferriols" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "es" => array:9 [ "pii" => "S0001731019302571" "doi" => "10.1016/j.ad.2019.06.002" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731019302571?idApp=UINPBA000044" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1578219019303749?idApp=UINPBA000044" "url" => "/15782190/0000011100000001/v2_202004200619/S1578219019303749/v2_202004200619/en/main.assets" ] "en" => array:21 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Brief Comunication</span>" "titulo" => "Oral atenolol for infantile hemangioma: case series of 46 infants" "tieneTextoCompleto" => true "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "59" "paginaFinal" => "62" ] ] "autores" => array:1 [ 0 => array:4 [ "autoresLista" => "X Calderón-Castrat, F Velásquez, R Castro, R Ballona" "autores" => array:4 [ 0 => array:4 [ "nombre" => "X" "apellidos" => "Calderón-Castrat" "email" => array:1 [ 0 => "xime_777@hotmail.com" ] "referencia" => array:2 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0005" ] 1 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">*</span>" "identificador" => "cor0005" ] ] ] 1 => array:3 [ "nombre" => "F" "apellidos" => "Velásquez" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">b</span>" "identificador" => "aff0010" ] ] ] 2 => array:3 [ "nombre" => "R" "apellidos" => "Castro" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0005" ] ] ] 3 => array:3 [ "nombre" => "R" "apellidos" => "Ballona" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">b</span>" "identificador" => "aff0010" ] ] ] ] "afiliaciones" => array:2 [ 0 => array:3 [ "entidad" => "Servicio de Dermatología Pediátrica y Unidad de Anomalías Vasculares, Instituto Nacional de Salud del Niño, San Borja, Peru" "etiqueta" => "a" "identificador" => "aff0005" ] 1 => array:3 [ "entidad" => "Servicio de Dermatología Pediátrica, Instituto Nacional de Salud del Niño, Breña, Peru" "etiqueta" => "b" "identificador" => "aff0010" ] ] "correspondencia" => array:1 [ 0 => array:3 [ "identificador" => "cor0005" "etiqueta" => "⁎" "correspondencia" => "Corresponding author." ] ] ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Atenolol oral en el manejo del hemangioma infantil: serie de casos de 46 pacientes" ] ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:8 [ "identificador" => "fig0005" "etiqueta" => "Fig. 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 1266 "Ancho" => 2007 "Tamanyo" => 323122 ] ] "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at0005" "detalle" => "Fig. " "rol" => "short" ] ] "descripcion" => array:1 [ "en" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">Clinical photographs of a 7-month-old girl with a mixed focal ulcerated IH of the major labia and two 4-month-old girls with a superficial focal ulcerated IH of the buttocks treated with oral atenolol showing changes in the color, size and wound closure at baseline <span class="elsevierStyleBold">(a,e, i),</span> 2 weeks <span class="elsevierStyleBold">(b,f,j</span>), 4 months <span class="elsevierStyleBold">(c,g,k),</span> and 6 months <span class="elsevierStyleBold">(d,h,l)</span>.</p>" ] ] ] "textoCompleto" => "<span class="elsevierStyleSections"><span id="sec0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0025">Introduction</span><p id="par0005" class="elsevierStylePara elsevierViewall">Infantile hemangioma (IH) is the most common benign tumor of infancy.<a class="elsevierStyleCrossRefs" href="#bib0005"><span class="elsevierStyleSup">1,2</span></a> The mainstay treatment for problematic IH to date is oral propranolol, a non-selective beta-blocker.<a class="elsevierStyleCrossRef" href="#bib0010"><span class="elsevierStyleSup">2</span></a> However, a minority of patients undergoing this treatment experience undesirable side effects, which limit its use.<a class="elsevierStyleCrossRefs" href="#bib0015"><span class="elsevierStyleSup">3–5</span></a> The current report describes a multi-center experience with oral atenolol, a selective beta-1 blocker, in 46 patients with IH, demonstrating its efficacy and side effects.</p></span><span id="sec0010" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0030">Materials and methods</span><p id="par0010" class="elsevierStylePara elsevierViewall">Forty-six infants treated between August 2016 and March 2018 were included from two National Institutes of Pediatric Health in Lima, Peru. All IH required treatment for functional risk, cosmetic disfigurement, and lack of response to prior treatments or side effects due to propranolol. This study was not assessed by and ethical committee review. The parents of the patients received information about the effects and side effects of the treatment and gave their consent before starting treatment (<a class="elsevierStyleCrossRef" href="#fig0005">Figs. 1</a>–<a class="elsevierStyleCrossRef" href="#fig0010">2</a>). Physical examination, baseline electrocardiogram and a pediatric cardiologist evaluation were required for all patients started on atenolol. During follow-up heart rate and blood pressure were registered in every visit.</p><elsevierMultimedia ident="fig0005"></elsevierMultimedia><elsevierMultimedia ident="fig0010"></elsevierMultimedia><p id="par0015" class="elsevierStylePara elsevierViewall">Treatment with oral atenolol 1<span class="elsevierStyleHsp" style=""></span>mg/kg in a daily dose was indicated in all patients in an outpatient environment. Atenolol dosage was adjusted according to weight gain in every monthly control and if inadequate response was observed, the dosage was increased to a maximum of 3<span class="elsevierStyleHsp" style=""></span>mg/kg. Controls with photographic documentation at baseline, 2 weeks and monthly until the end of treatment were performed. Clinical involution was assessed in every control in the outpatient clinic evaluating color change, softening upon palpation and size reduction supported by clinical photographs. Treatment outcome was determined as complete involution; (presence of telangiectasia or residual fibroadipose tissue), partial regression and no response. Side effects were recorded in every visit.</p></span><span id="sec0015" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0035">Results</span><p id="par0020" class="elsevierStylePara elsevierViewall">The study consisted of 46 infants, 35/46 (76,1 %) females and 11/46 (23,9 %) males presenting with a total of 55 IH. Sixty-one percent (61,8 %) of IH were located in the head and neck area, 16,4 % extremities, 14,5 % genitals and 7,3 % trunk. By type, 60 % of IH were superficial, 32,7 % mixed and 7,3 % deep. Of all IH, 12,7 % presented ulceration. Four patients in our series had undergone treatment with propranolol suspended on account of side effects. The mean age at the start of the treatment with atenolol was 4,35 months (range of age between 1 and 34 months).</p><p id="par0025" class="elsevierStylePara elsevierViewall">Treatment duration lasted on average 6,4 months (range 4–17 months). All patients responded to the treatment with oral atenolol. Complete involution in 61,8 % and partial regression in 38,2 % of patients was observed. Ulcerated IH presented complete wound closure at a mean time of 16,4 days (<a class="elsevierStyleCrossRef" href="#fig0005">Fig. 1</a>). No recurrence was observed after discontinuation of treatment. Twenty-three percent (23,9 %) of patients presented mild side effects. The main side effect reported was limited to mild transient diarrhea. Only one patient presented mild sleep disturbance at the start of treatment with spontaneous resolution. No adverse events such as hypoglycemia, bronchospasm, bradycardia, or hypotension were reported.</p></span><span id="sec0020" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0040">Discussion</span><p id="par0030" class="elsevierStylePara elsevierViewall">Since its FDA approval in 2014, propranolol, a lipophilic, non-selective beta-adrenergic blocker, remains the mainstay treatment for IH.<a class="elsevierStyleCrossRefs" href="#bib0005"><span class="elsevierStyleSup">1,2</span></a> However, propranolol rarely may present undesired side effects and thus the interest for alternatives with similar efficacy have been considered recently.<a class="elsevierStyleCrossRefs" href="#bib0015"><span class="elsevierStyleSup">3,4</span></a> Atenolol is a hydrophilic, selective beta-1 blocker and its mechanism of action on IH is currently unknown.<a class="elsevierStyleCrossRefs" href="#bib0020"><span class="elsevierStyleSup">4,5</span></a> Several advantages in comparison with propranolol however have been observed. First, by avoiding beta-2 receptors, bronchial hyperreactivity and hypoglycemia are avoided. Second, its hydrophilic property reduces the passage to the blood brain barrier and consequently reduces sleep disturbances.<a class="elsevierStyleCrossRef" href="#bib0030"><span class="elsevierStyleSup">6</span></a> Atenolol is also administered once daily and therefore provides a better patient adherence to the medication.<a class="elsevierStyleCrossRefs" href="#bib0020"><span class="elsevierStyleSup">4–8</span></a></p><p id="par0035" class="elsevierStylePara elsevierViewall">Previously, the only randomized comparative study of atenolol versus propranolol, demonstrated similar efficacy with fewer side effects in regards with respiratory bronchospasm.<a class="elsevierStyleCrossRef" href="#bib0020"><span class="elsevierStyleSup">4</span></a> Subsequent studies have sustained similar consistency with these results.<a class="elsevierStyleCrossRefs" href="#bib0025"><span class="elsevierStyleSup">5,7,8</span></a> In our case series, we achieved to demonstrate great results with atenolol while no adverse side effects were noted. Another interesting result is the rapid response in the seven ulcerated IH with atenolol. Although it is a small subgroup of our treated IH, comparatively a previous study showed on average 8 weeks fo full healing of the wound.<a class="elsevierStyleCrossRef" href="#bib0045"><span class="elsevierStyleSup">9</span></a> All our ulcerated IH were additionally indicated zinc sulfate 1 % (15<span class="elsevierStyleHsp" style=""></span>ml in 50<span class="elsevierStyleHsp" style=""></span>ml of water) 2 times daily as topical cures, until complete epithelization was achieved.</p></span><span id="sec0025" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0045">Conclusion</span><p id="par0040" class="elsevierStylePara elsevierViewall">We present a non-randomised, non-blinded case series of 46 patients with IH treated successfully with oral atenolol. Our findings are based on clinical observations. Taking into account these limitations, oral atenolol has proved to be an effective and safe alternative for problematic IH.</p><p id="par0045" class="elsevierStylePara elsevierViewall">We propose atenolol as a possible first line treatment. Even though our study has its limitations, it serves to provide further clinical evidence for future formal comparative studies to assess the effectiveness of atenolol versus propranolol to verify our findings.</p></span></span>" "textoCompletoSecciones" => array:1 [ "secciones" => array:11 [ 0 => array:3 [ "identificador" => "xres1327533" "titulo" => "Abstract" "secciones" => array:1 [ 0 => array:1 [ "identificador" => "abst0005" ] ] ] 1 => array:2 [ "identificador" => "xpalclavsec1223714" "titulo" => "Keywords" ] 2 => array:3 [ "identificador" => "xres1327532" "titulo" => "Resumen" "secciones" => array:1 [ 0 => array:1 [ "identificador" => "abst0010" ] ] ] 3 => array:2 [ "identificador" => "xpalclavsec1223715" "titulo" => "Palabras claves" ] 4 => array:2 [ "identificador" => "sec0005" "titulo" => "Introduction" ] 5 => array:2 [ "identificador" => "sec0010" "titulo" => "Materials and methods" ] 6 => array:2 [ "identificador" => "sec0015" "titulo" => "Results" ] 7 => array:2 [ "identificador" => "sec0020" "titulo" => "Discussion" ] 8 => array:2 [ "identificador" => "sec0025" "titulo" => "Conclusion" ] 9 => array:2 [ "identificador" => "xack458288" "titulo" => "Acknowledgments" ] 10 => array:1 [ "titulo" => "References" ] ] ] "pdfFichero" => "main.pdf" "tienePdf" => true "fechaRecibido" => "2018-03-19" "fechaAceptado" => "2019-03-03" "PalabrasClave" => array:2 [ "en" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Keywords" "identificador" => "xpalclavsec1223714" "palabras" => array:7 [ 0 => "Vascular anomalies" 1 => "Vascular tumors" 2 => "Infantile hemangioma" 3 => "Atenolol" 4 => "Propranolol" 5 => "Beta-Blockers" 6 => "Systemic treatment" ] ] ] "es" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Palabras claves" "identificador" => "xpalclavsec1223715" "palabras" => array:7 [ 0 => "Anomalías vasculares" 1 => "Tumores vasculares" 2 => "Hemangioma infantil" 3 => "Atenolol" 4 => "Propranolol" 5 => "Tratamiento sistémico" 6 => "Beta-Bloqueantes." ] ] ] ] "tieneResumen" => true "resumen" => array:2 [ "en" => array:2 [ "titulo" => "Abstract" "resumen" => "<span id="abst0005" class="elsevierStyleSection elsevierViewall"><p id="spar0015" class="elsevierStyleSimplePara elsevierViewall">Propranolol a non-selective beta-blocker, remains the first line of treatment for problematic infantile hemangioma. However, although rarely, a subset of patients experience undesirable side effects, raising interest in other selective beta-blockers. We present a large case series of 46 infants treated successfully with oral atenolol, a selective beta-1 blocker.</p></span>" ] "es" => array:2 [ "titulo" => "Resumen" "resumen" => "<span id="abst0010" class="elsevierStyleSection elsevierViewall"><p id="spar0020" class="elsevierStyleSimplePara elsevierViewall">El propranolol, un betabloqueante no selectivo, sigue siendo la primera línea de tratamiento para el hemangioma infantil problemático. Sin embargo, aunque poco frecuente, un subgrupo de pacientes experimenta efectos secundarios indeseables, lo que despierta el interés sobre otros beta-bloqueantes selectivos. Presentamos una amplia serie de casos de 46 lactantes tratados con éxito con atenolol, un bloqueante selectivo beta 1.</p></span>" ] ] "NotaPie" => array:1 [ 0 => array:2 [ "etiqueta" => "☆" "nota" => "<p class="elsevierStyleNotepara" id="npar0005">Please cite this article as: Calderón-Castrat X., Velásquez F., Castro R., Ballona R. Atenolol oral en el manejo del hemangioma infantil: serie de casos de 46 pacientes. Actas Dermosifiliogr. 2020;111:59–62.</p>" ] ] "multimedia" => array:2 [ 0 => array:8 [ "identificador" => "fig0005" "etiqueta" => "Fig. 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 1266 "Ancho" => 2007 "Tamanyo" => 323122 ] ] "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at0005" "detalle" => "Fig. " "rol" => "short" ] ] "descripcion" => array:1 [ "en" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">Clinical photographs of a 7-month-old girl with a mixed focal ulcerated IH of the major labia and two 4-month-old girls with a superficial focal ulcerated IH of the buttocks treated with oral atenolol showing changes in the color, size and wound closure at baseline <span class="elsevierStyleBold">(a,e, i),</span> 2 weeks <span class="elsevierStyleBold">(b,f,j</span>), 4 months <span class="elsevierStyleBold">(c,g,k),</span> and 6 months <span class="elsevierStyleBold">(d,h,l)</span>.</p>" ] ] 1 => array:8 [ "identificador" => "fig0010" "etiqueta" => "Fig. 2" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr2.jpeg" "Alto" => 2314 "Ancho" => 2007 "Tamanyo" => 467351 ] ] "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at0010" "detalle" => "Fig. " "rol" => "short" ] ] "descripcion" => array:1 [ "en" => "<p id="spar0010" class="elsevierStyleSimplePara elsevierViewall">Clinical photographs of a 2-month-old girl with a mixed nasal IH and a 4-month-old girl with a mixed parotid IH treated with oral atenolol showing changes in size at baseline <span class="elsevierStyleBold">(a,e,i),</span> 1 month <span class="elsevierStyleBold">(b,f)</span> 2 months <span class="elsevierStyleBold">(c,g)</span> and 4 months <span class="elsevierStyleBold">(d,h,j)</span>.</p>" ] ] ] "bibliografia" => array:2 [ "titulo" => "References" "seccion" => array:1 [ 0 => array:2 [ "identificador" => "bibs0005" "bibliografiaReferencia" => array:9 [ 0 => array:3 [ "identificador" => "bib0005" "etiqueta" => "1" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Propranolol for severe hemangiomas of infancy" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "C. Léauté-Labréze" 1 => "E. Dumas de la Roque" 2 => "T. Hubiche" 3 => "F. Boralevi" 4 => "J.B. Thambo" 5 => "A. Taïeb" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1056/NEJMc0708819" "Revista" => array:6 [ "tituloSerie" => "N Engl J Med." "fecha" => "2008" "volumen" => "358" "paginaInicial" => "2649" "paginaFinal" => "2651" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/18550886" "web" => "Medline" ] ] ] ] ] ] ] ] 1 => array:3 [ "identificador" => "bib0010" "etiqueta" => "2" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The use of propranolol in the treatment of infantile haemangiomas: an update on potential mechanisms of action" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "Y. Ji" 1 => "S. Chen" 2 => "C. Xu" 3 => "L. Li" 4 => "B. Xiang" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/bjd.13388" "Revista" => array:6 [ "tituloSerie" => "Br J Dermatol." "fecha" => "2015" "volumen" => "172" "paginaInicial" => "24" "paginaFinal" => "32" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/25196392" "web" => "Medline" ] ] ] ] ] ] ] ] 2 => array:3 [ "identificador" => "bib0015" "etiqueta" => "3" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Atenolol: a promising alternative to propranolol for the treatment of hemangiomas" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "M.F. Raphael" 1 => "M. de Graaf" 2 => "C.C. Breugem" 3 => "S.G.M.A. Pasmans" 4 => "J.M.P.J. Breur" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.jaad.2010.11.056" "Revista" => array:6 [ "tituloSerie" => "J Am Acad Dermatol." "fecha" => "2011" "volumen" => "65" "paginaInicial" => "420" "paginaFinal" => "421" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/21763565" "web" => "Medline" ] ] ] ] ] ] ] ] 3 => array:3 [ "identificador" => "bib0020" "etiqueta" => "4" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Atenolol versus propranolol for the treatment of infantile hemangiomas: a randomized controlled study" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "A. Abarzua-Araya" 1 => "C.P. Navarrete-Dechent" 2 => "F. Heusser" 3 => "J. Retamal" 4 => "M.S. Zegpi-Trueba" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.jaad.2014.01.905" "Revista" => array:6 [ "tituloSerie" => "J Am Acad Dermatol." "fecha" => "2014" "volumen" => "70" "paginaInicial" => "1045" "paginaFinal" => "1049" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/24656727" "web" => "Medline" ] ] ] ] ] ] ] ] 4 => array:3 [ "identificador" => "bib0025" "etiqueta" => "5" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Atenolol versus propranolol for treatment of infantile hemangiomas during the proliferative phase: a retrospective noninferiority study" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "C.B. Bayart" 1 => "J.E. Tamburro" 2 => "A.T. Vidimos" 3 => "L. Wang" 4 => "A.B. Golden" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/pde.13177" "Revista" => array:6 [ "tituloSerie" => "Pediatr Dermatol." "fecha" => "2017" "volumen" => "34" "paginaInicial" => "413" "paginaFinal" => "421" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/28556385" "web" => "Medline" ] ] ] ] ] ] ] ] 5 => array:3 [ "identificador" => "bib0030" "etiqueta" => "6" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Atenolol treatment for infantile haemangioma" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "M. Tasani" 1 => "M. Glover" 2 => "A.E. Martinez" 3 => "L. Shaw" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/bjd.15317" "Revista" => array:6 [ "tituloSerie" => "Br J Dermatol." "fecha" => "2017" "volumen" => "176" "paginaInicial" => "1400" "paginaFinal" => "1402" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/28112790" "web" => "Medline" ] ] ] ] ] ] ] ] 6 => array:3 [ "identificador" => "bib0035" "etiqueta" => "7" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Oral atenolol therapy for proliferating infantile hemangioma: a prospective study" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "Y. Ji" 1 => "Q. Wang" 2 => "S. Chen" 3 => "B. Xiang" 4 => "Z. Xu" 5 => "Y. Li" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1097/MD.0000000000003908" "Revista" => array:5 [ "tituloSerie" => "Medicine (Baltimore)." "fecha" => "2016" "volumen" => "95" "paginaInicial" => "e3908" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/27310994" "web" => "Medline" ] ] ] ] ] ] ] ] 7 => array:3 [ "identificador" => "bib0040" "etiqueta" => "8" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Treatment of infantile haemangiomas with atenolol: comparison with a historical propranolol group" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "M. De Graaf" 1 => "M.F. Raphael" 2 => "C.C. Breugem" 3 => "C.A. Bruijnzeel-Koomen" 4 => "M. Kon" 5 => "J.M. Breur" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.bjps.2013.07.035" "Revista" => array:6 [ "tituloSerie" => "J Plast Reconstr Aesthet Surg." "fecha" => "2013" "volumen" => "66" "paginaInicial" => "1732" "paginaFinal" => "1740" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/24011909" "web" => "Medline" ] ] ] ] ] ] ] ] 8 => array:3 [ "identificador" => "bib0045" "etiqueta" => "9" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Ulcerated infantile haemangiomas: the effect of the selective beta-blocker atenolol on wound Healing" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "G. Ruitenberg" 1 => "D.A. Young-Afat" 2 => "M. de Graaf" 3 => "S.G. Pasmans" 4 => "C.C. Breugem" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/bjd.14687" "Revista" => array:6 [ "tituloSerie" => "Br J Dermatol." "fecha" => "2016" "volumen" => "175" "paginaInicial" => "1357" "paginaFinal" => "1360" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/27105937" "web" => "Medline" ] ] ] ] ] ] ] ] ] ] ] ] "agradecimientos" => array:1 [ 0 => array:4 [ "identificador" => "xack458288" "titulo" => "Acknowledgments" "texto" => "<p id="par0050" class="elsevierStylePara elsevierViewall">We thank our patients’ parents for their cooperation, support, and for providing their consent regarding the clinical images for publication of this manuscript.</p>" "vista" => "all" ] ] ] "idiomaDefecto" => "en" "url" => "/15782190/0000011100000001/v2_202004200619/S1578219019303452/v2_202004200619/en/main.assets" "Apartado" => array:4 [ "identificador" => "76905" "tipo" => "SECCION" "en" => array:2 [ "titulo" => "Brief Comunications" "idiomaDefecto" => true ] "idiomaDefecto" => "en" ] "PDF" => "https://static.elsevier.es/multimedia/15782190/0000011100000001/v2_202004200619/S1578219019303452/v2_202004200619/en/main.pdf?idApp=UINPBA000044&text.app=https://actasdermo.org/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1578219019303452?idApp=UINPBA000044" ]
Year/Month | Html | Total | |
---|---|---|---|
2024 November | 6 | 10 | 16 |
2024 October | 84 | 52 | 136 |
2024 September | 88 | 27 | 115 |
2024 August | 112 | 81 | 193 |
2024 July | 106 | 41 | 147 |
2024 June | 118 | 71 | 189 |
2024 May | 126 | 35 | 161 |
2024 April | 114 | 29 | 143 |
2024 March | 98 | 29 | 127 |
2024 February | 82 | 33 | 115 |
2024 January | 91 | 32 | 123 |
2023 December | 74 | 18 | 92 |
2023 November | 72 | 40 | 112 |
2023 October | 61 | 37 | 98 |
2023 September | 56 | 34 | 90 |
2023 August | 57 | 15 | 72 |
2023 July | 85 | 33 | 118 |
2023 June | 48 | 16 | 64 |
2023 May | 78 | 21 | 99 |
2023 April | 60 | 20 | 80 |
2023 March | 70 | 28 | 98 |
2023 February | 66 | 28 | 94 |
2023 January | 42 | 26 | 68 |
2022 December | 51 | 34 | 85 |
2022 November | 45 | 13 | 58 |
2022 October | 28 | 17 | 45 |
2022 September | 23 | 43 | 66 |
2022 August | 32 | 43 | 75 |
2022 July | 21 | 40 | 61 |
2022 June | 25 | 24 | 49 |
2022 May | 38 | 47 | 85 |
2022 April | 40 | 30 | 70 |
2022 March | 47 | 53 | 100 |
2022 February | 60 | 22 | 82 |
2022 January | 47 | 32 | 79 |
2021 December | 41 | 30 | 71 |
2021 November | 42 | 33 | 75 |
2021 October | 42 | 47 | 89 |
2021 September | 19 | 33 | 52 |
2021 August | 50 | 25 | 75 |
2021 July | 53 | 24 | 77 |
2021 June | 60 | 19 | 79 |
2021 May | 64 | 63 | 127 |
2021 April | 248 | 103 | 351 |
2021 March | 113 | 46 | 159 |
2021 February | 92 | 57 | 149 |
2021 January | 65 | 32 | 97 |
2020 December | 43 | 21 | 64 |
2020 November | 21 | 26 | 47 |
2020 October | 39 | 18 | 57 |
2020 September | 44 | 31 | 75 |
2020 August | 42 | 13 | 55 |
2020 July | 41 | 10 | 51 |
2020 June | 35 | 18 | 53 |
2020 May | 42 | 21 | 63 |
2020 April | 52 | 25 | 77 |
2020 March | 58 | 24 | 82 |
2020 February | 1 | 2 | 3 |
2020 January | 7 | 2 | 9 |